panitumumab
- Generic Name
- panitumumab
- Brand Names
- Vectibix
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 339177-26-3
- Unique Ingredient Identifier
- 6A901E312A
- Background
Panitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent.
Panitumumab was granted FDA approval on 27 September 2006.
- Indication
美国FDA批准：用于野生型KRAS(外显子2)转移性结直肠癌(mCRC)患者的一线治疗。
- Associated Conditions
- Metastatic Colorectal Cancer (CRC)
- Associated Therapies
- -
PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence
- First Posted Date
- 2021-03-08
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 214
- Registration Number
- NCT04787341
- Locations
- 🇮🇹
U.O. Oncologia 2 Universitaria, Pisa, PI, Italy
Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC
- Conditions
- Interventions
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 71
- Registration Number
- NCT04587128
- Locations
- 🇺🇸
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2022-04-07
- Lead Sponsor
- National Cancer Institute, Naples
- Target Recruit Count
- 151
- Registration Number
- NCT04425239
- Locations
- 🇮🇹
Istituto Nazionale Tumori di Napoli - IRCCS - Fondazione G. Pascale, Napoli, Italy
Lymph Node Ratio and Kras Mutation in R Colon Cancer
- First Posted Date
- 2020-04-13
- Last Posted Date
- 2020-04-13
- Lead Sponsor
- Mansoura University
- Target Recruit Count
- 433
- Registration Number
- NCT04342676
- Locations
- 🇪🇬
Mansoura University Oncology Center, Mansoura, Ad Daqahliyah, Egypt
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
- Conditions
- Interventions
- Drug: SotorasibDrug: RMC-4630Drug: AfatinibDrug: MVASI® (bevacizumab-awwb)Drug: AtezolizumabDrug: TNO155Drug: BI 1701963Drug: AMG 404Drug: TrametinibDrug: PembrolizumabDrug: PalbociclibDrug: EverolimusDrug: IV Chemotherapy (Regimen 1)Drug: Carboplatin, pemetrexed, docetaxel, paclitaxelDrug: PanitumumabDrug: IV Chemotherapy (Regimen 2)
- First Posted Date
- 2019-12-04
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Amgen
- Target Recruit Count
- 1200
- Registration Number
- NCT04185883
- Locations
- 🇺🇸
Henry Ford Cancer Detroit (Brigitte Harris Cancer Pavilion), Detroit, Michigan, United States
🇺🇸Arizona Oncology Associates Professional Corporation, Tucson, Arizona, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer
- Conditions
- BRAF V600E NegativeMetastatic Colorectal AdenocarcinomaNRAS Gene Mutation NegativeKRAS Gene Mutation NegativeStage IVA Colorectal Cancer AJCC v8Stage IVB Colorectal Cancer AJCC v8Stage IVC Colorectal Cancer AJCC v8Locally Advanced Unresectable Colorectal AdenocarcinomaStage III Colorectal Cancer AJCC v8Stage IIIB Colorectal Cancer AJCC v8
- Interventions
- First Posted Date
- 2019-10-07
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Academic and Community Cancer Research United
- Target Recruit Count
- 22
- Registration Number
- NCT04117945
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸MedStar Georgetown University Hospital, Washington, District of Columbia, United States
Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation
- Conditions
- Interventions
- First Posted Date
- 2019-07-26
- Last Posted Date
- 2019-07-26
- Lead Sponsor
- Ludwig-Maximilians - University of Munich
- Target Recruit Count
- 120
- Registration Number
- NCT04034173
- Locations
- 🇩🇪
Ludwigs Maximialians University, Munich, Germany
Re-challenge Therapy With Chemotherapy & Panitumumab in Metastatic Colorectal Cancer Patients Treated With an Anti-EGFR
- First Posted Date
- 2019-05-07
- Last Posted Date
- 2022-04-06
- Lead Sponsor
- King Abdullah Medical City
- Target Recruit Count
- 30
- Registration Number
- NCT03940131
- Locations
- 🇸🇦
King Abdullah Medical City, Holy Capital, Mecca, Makkah Western, Saudi Arabia
Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal
- Conditions
- Interventions
- First Posted Date
- 2018-11-23
- Last Posted Date
- 2021-06-30
- Target Recruit Count
- 31
- Registration Number
- NCT03751176
- Locations
- 🇪🇸
ICO Girona Dr. Josep Trueta, Gerona, Barcelona, Spain
🇪🇸Hospital de Granollers, Granollers, Barcelona, Spain
🇪🇸Hospital Mutua de Terrassa, Terrassa, Barcelona, Spain
Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-08-17
- Last Posted Date
- 2024-10-21
- Target Recruit Count
- 419
- Registration Number
- NCT03635021
- Locations
- 🇪🇸
Spanish Cooperative Group for the Treatment of Digestive Tumors, Madrid, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.